You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
嘉和生物-B(06998.HK):GB492臨牀試驗獲國家藥監局批准
格隆匯 05-20 08:52

格隆匯5月20日丨嘉和生物-B(06998.HK)公佈,公司收到國家藥品監督管理局關於GB492(IMSA101)干擾素基因刺激因子(S Timulator of interferongenes,STING)的臨牀試驗批准。該I/IIa期臨牀試驗會評估GB492單藥以及與PD-(L)1單克隆抗體聯合在晚期╱難治性惡性腫瘤患者中的安全性和有效性。

董事會亦欣然宣佈,公司已委任德克薩斯大學西南醫學中心分子生物學教授兼研究員陳志堅博士為公司的科學顧問委員會(Scientific Advisory Board)主席。陳博士擁有豐富的STING通路研究與探索經驗。

GB492(IMSA101)干擾素基因刺激因子(S Timulator of interferongenes,STING)是癌細胞固有免疫感知的主要介導體,由集團於2020年6月向Immune Sensor Therapeutic獲得獨家許可協議。STING激動劑,作為一種免疫刺激療法,將進一步增加患者對免疫檢查點抑制劑的反應。多項研究顯示,STING激動劑與其他免疫檢查點抑制劑(ICI)聯合使用可激活cGAS-STING信號通路,顯着增強腫瘤免疫週期的療效,將成為一種創新療法。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account